Integer Holdings Faces Securities Class Action as Shares Plunge 32%
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 30 minutes ago0mins
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased Integer Holdings shares between July 25, 2024, and October 22, 2025, that they must file lead plaintiff applications by February 9, 2026, to seek recovery for economic losses.
- Guidance Downgrade: On October 23, 2025, Integer lowered its full-year sales guidance to between $1.840 billion and $1.854 billion, significantly below analyst expectations, with projected net sales growth of -2% to 2% for 2026, indicating slower market adoption of its products.
- Stock Price Plunge: Following the earnings warning, Integer's shares fell by $35.22, or over 32%, from a closing price of $109.11 on October 22, 2025, to $73.89 on October 23, reflecting a pessimistic market outlook on the company's future.
- Legal Implications: The lawsuit alleges that Integer and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to greater legal and financial risks.
ITGR.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 71.950
Low
69.00
Averages
91.75
High
140.00
Current: 71.950
Low
69.00
Averages
91.75
High
140.00
Citi
Neutral
maintain
$69 -> $75
2025-12-11
New
Reason
Citi
Price Target
$69 -> $75
2025-12-11
New
maintain
Neutral
Reason
Citi raised the firm's price target on Integer to $75 from $69 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
Truist
Buy
downgrade
$88 -> $86
2025-11-24
Reason
Truist
Price Target
$88 -> $86
2025-11-24
downgrade
Buy
Reason
Truist lowered the firm's price target on Integer to $86 from $88 and keeps a Buy rating on the shares. Following the firm's meeting with the company CEO, Truist continues to believe that it could take a few quarters before investors underwrite a re-acceleration in the second half of FY26, the analyst tells investors in a research note.
Citi
Neutral
downgrade
$77 -> $69
2025-11-03
Reason
Citi
Price Target
$77 -> $69
2025-11-03
downgrade
Neutral
Reason
Citi lowered the firm's price target on Integer to $69 from $77 and keeps a Neutral rating on the shares.
Benchmark
Robert Wasserman
Buy
to
Hold
downgrade
2025-10-24
Reason
Benchmark
Robert Wasserman
Price Target
2025-10-24
downgrade
Buy
to
Hold
Reason
Benchmark analyst Robert Wasserman downgraded Integer to Hold from Buy with no price target after management lowered guidance for FY25 and "perhaps most damaging," initiated a flat-to-lower outlook for FY26 due to reduced demand for three products that the company manufactures. The firm is lowering its rating until the company can return to growth mode, the analyst tells investors.
See All Ratings
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?